Biopharma scores a $5bn quarter as another big year builds for venture financing.
Shareholders are rewarding the kinds of companies they punished a year ago.
If the first quarter was quiet for takeovers the second saw M&A grind to a halt. What can the matter be?
IPOs of drug developers raised $9bn in the first half of 2021, a record amount that is hard to square with talk of moderation.
Two huge up-front fees this week, for an anti-Tigit MAb and an antibody-drug conjugate, show that early-stage oncology assets are still hot.
Biogen’s Aduhelm was the big one, but there are plenty of other key regulatory decisions still pending this year.
Find out where the venture money has been flowing in our new report on biopharma investment trends, free to download now.
As Covid-19 spending pushes the sector’s R&D bill ever higher, Lilly continues to plough the most back in as Sanofi applies the brakes.
Huge hopes for diabetes and Alzheimer’s projects swell Lilly’s pipeline valuation, with Glaxosmithkline and Abbvie looking bare in comparison.